Linked Life Data

15289739

Source:http://linkedlifedata.com/resource/pubmed/id/15289739

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2004-8-3
pubmed:abstractText
The purpose of this study was to investigate the impact of survivin, cyclin D1, integrin beta1, and vascular endothelial growth factor (VEGF) in tumor on survival of patients with small adenocarcinoma of the lung. Seventy-two patients with pathologic stage I resected tumors <2 cm in diameter were entered into the study. Each patient underwent curative surgical resection for lung cancer between July 1992 and November 1999. The resected tumors were subjected to immunostaining for each gene. Thirty-five, 26, 6, and 16 patients had tumors with >10% survivin-, >20% cyclin D1-, >10% integrin beta1-, and >10% VEGF-positive cells, respectively. When the survival of 72 patients was compared according to each gene expression, the overall survival of patients with positive expression of survivin, cyclin D1, and integrin [beta]1 was significantly worse than that of individuals whose tumors had negative expression of each gene. By multivariate analysis controlling for each gene expression, no gene expression was an independent marker of poor prognosis, however, the overall survival of the complex gene expression (2 or more gene-positive) group (n = 35) was significantly worse than that of 0 or 1 gene-positive group (n = 37; log-rank test, P = 0.0011; Wilcoxon test, P = 0.0011). When the association between survival and pathologic factors, including lymphatic invasion, venous invasion, type of bronchioalveolar carcinoma, and complex gene positive expression was analyzed, only complex gene-positive expression was found to be a significant independent factor (hazard ratio = 0.085, P = 0.0299). It can be concluded that multiple increased expression of oncogene is a poor prognostic factor in patients with small adenocarcinoma of the lung.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1537-453X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
425-8
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:15289739-Adenocarcinoma, pubmed-meshheading:15289739-Adult, pubmed-meshheading:15289739-Aged, pubmed-meshheading:15289739-Aged, 80 and over, pubmed-meshheading:15289739-Antigens, CD29, pubmed-meshheading:15289739-Biological Markers, pubmed-meshheading:15289739-Cyclin D1, pubmed-meshheading:15289739-Female, pubmed-meshheading:15289739-Gene Expression, pubmed-meshheading:15289739-Humans, pubmed-meshheading:15289739-Immunohistochemistry, pubmed-meshheading:15289739-Inhibitor of Apoptosis Proteins, pubmed-meshheading:15289739-Lung Neoplasms, pubmed-meshheading:15289739-Male, pubmed-meshheading:15289739-Microtubule-Associated Proteins, pubmed-meshheading:15289739-Middle Aged, pubmed-meshheading:15289739-Neoplasm Proteins, pubmed-meshheading:15289739-Prognosis, pubmed-meshheading:15289739-Survival Analysis, pubmed-meshheading:15289739-Vascular Endothelial Growth Factor A
pubmed:year
2004
pubmed:articleTitle
Prognostic impact of survivin, cyclin D1, integrin beta1, and VEGF in patients with small adenocarcinoma of stage I lung cancer.
pubmed:affiliation
Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan. foshita@kcch.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't